Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E28.37 EPS (ttm)1.22 Insider Own0.10% Shs Outstand6.15B Perf Week2.58%
Market Cap212.85B Forward P/E13.22 EPS next Y2.62 Insider Trans-13.45% Shs Float6.06B Perf Month6.11%
Income7.59B PEG3.63 EPS next Q0.62 Inst Own76.50% Short Float1.39% Perf Quarter17.69%
Sales50.99B P/S4.17 EPS this Y-21.50% Inst Trans1.44% Short Ratio1.88 Perf Half Y7.30%
Book/sh10.25 P/B3.38 EPS next Y7.34% ROA- Target Price38.62 Perf Year3.12%
Cash/sh3.16 P/C10.95 EPS next 5Y7.82% ROE- 52W Range27.71 - 35.22 Perf YTD9.27%
Dividend1.20 P/FCF- EPS past 5Y1.60% ROI8.00% 52W High-1.72% Beta0.85
Dividend %3.47% Quick Ratio1.20 Sales past 5Y-5.60% Gross Margin79.20% 52W Low24.89% ATR0.44
Employees97900 Current Ratio1.40 Sales Q/Q19.70% Oper. Margin- RSI (14)76.47 Volatility1.08% 1.32%
OptionableYes Debt/Eq0.62 EPS Q/Q28.90% Profit Margin- Rel Volume0.46 Prev Close34.43
ShortableYes LT Debt/Eq0.44 EarningsMay 03 BMO Payout- Avg Volume44.80M Price34.61
Recom2.20 SMA203.65% SMA507.64% SMA2009.49% Volume20,445,151 Change0.52%
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jan-22-13Reiterated Barclays Equal Weight $24 → $25
May-29-16 10:15AM  Key Movers to Look for Ahead of ASCO at 24/7 Wall St.
May-28-16 02:52PM  Five Dividend Stocks Hedge Funds Love at Insider Monkey
02:18PM  Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline at Motley Fool
12:00PM  3 ETFs Affected by the Failed Pfizer-Allergan Merger (PFE, AGN) at Investopedia
09:40AM  Portola Pharmaceuticals: Does New Data Get It Back on Track? at Motley Fool
08:30AM  3 Stories To Watch At The Years Biggest Cancer Conference
May-27-16 04:16PM  Whats Allergans Growth Strategy?
04:16PM  How Do Allergans Valuations Compare to Its Peers?
03:31PM  This New Data Could Push Exelixis' Cabometyx Over $1 Billion in Peak Annual Sales at Motley Fool
09:43AM  2016 Global 2000: The World's Largest Drug And Biotech Companies at Forbes
09:15AM  Morning Technical Breakdown Highlights on Big Drug Makers Stocks
08:12AM  Flexion (FLXN) Zilretta Gets Positive FDA Guidance; Stock Up
05:43AM  2016 Global 2000: The World's Largest Drug And Biotech Companies
May-26-16 07:47PM  U.S. sees first case of bacteria resistant to all antibiotics Reuters
05:27PM  Anacor received rival bid before Pfizer deal - filing
03:36PM  Anacor reveals receiving rival bid before Pfizer deal - filing
01:56PM  Pharmaceuticals are the hottest thing in TV ads
11:24AM  Ionis Hits 2-Year Low As GlaxoSmithKline Drops Big Trial Plans
11:02AM  Behind Bristol-Myers Squibbs Continued Growth in 1Q16
10:43AM  Cancer Immunotherapies Take Center Stage in Pre-ASCO Abstract Releases at Motley Fool
10:38AM  Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference Business Wire
09:30AM  Applied Materials, Agrium, Pfizer and KB Home highlighted as Zacks Bull and Bear of the Day
09:09AM  Pfizer Offers Hope For Lower-Priced Cancer Drug Combos at Forbes
08:00AM  Biotech ETFs: Why Valeant May Cause Contagion Risk (VRX) at Investopedia
May-25-16 06:19PM  Buy Pfizer, Chevron, Newell Brands and Enjoy the Profits
01:13PM  Top Stock Picks for the Week of May 23rd
11:31AM  Pfizer Wants to Be Seen as an Oncology Powerhouse
10:05AM  4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends at 24/7 Wall St.
09:35AM  Could the Worlds Most Effective Quit Smoking Aid be a Low Nicotine Cigarette US Public Health Officials Think So
09:07AM  XBIs and IHIs Mid-Caps Soared, Overturning 2 Weeks of Losses
08:15AM  Short Sellers Take Mixed Stance on Major Pharma at 24/7 Wall St.
May-24-16 06:27PM  Richard Bernstein: Corporate Profit Cycle May Be Turning
06:04PM  Lilly says new type of pain drug could lessen need for opioids Reuters
05:41PM  Billionaires Are Bailing on Pfizer, Inc -- Should You? at Motley Fool
12:24PM  Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why at Motley Fool
10:19AM  XBI Was a Top Performer in the Biotechnology Sector
10:13AM  Billionaire Paul Singers Top Picks and New Bets for Q2 at Insider Monkey
09:58AM  4 Dow Members Bucking the Negative Trend
09:27AM  Pfizer Champix's Label to Include More Data, Warning Lifted
09:04AM  The Best Buys in Biopharma Today at Motley Fool
May-23-16 06:54PM  Pfizer Bets Big on Eczema With Anacor Acquisition at Investopedia
05:53PM  EU lifts suicide warning on Pfizer's smoking-cessation pill
05:30PM  Business Highlights
04:11PM  Pfizer (PFE) Stock Closed Down, European Drug Warning Lifted
02:28PM  Anti-Growth Policies Hurt Investors at Forbes
10:33AM  Pfizer's (PFE) Trumenba Accepted for Review in the EU
08:41AM  Pfizer Updates CHAMPIX To Add New Safety And Efficacy Data In European Union
07:13AM  These 3 Big Stocks Are Flashing Buy Signals on Big Volume
07:00AM  Europe lifts warning on Pfizer smoking cessation drug Reuters
07:00AM  CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP Business Wire
06:02AM  CF Industries Pulls $8B Takeover of OCI Assets
May-22-16 11:38AM  3 Stocks Senior Citizens Could Buy Now at Motley Fool
May-21-16 09:40AM  Here's What Pfizer's Telling Us About Biotech M&A at Motley Fool
May-20-16 09:06AM  Pfizer, Biogen Can Fancy Acadia for Takeover
09:03AM  Pfizer Gets European Regulator Acceptance For Review Of Marketing For TRUMENBA
08:36AM  Four reasons for investors to buy biotechnology stocks now at MarketWatch
08:00AM  Pfizer Announces European Medicines Agency Acceptance for Review of Marketing Authorization Application for TRUMENBA® (Meningococcal Group B Vaccine) Business Wire
06:00AM  On BizWireTV: Streaming Service Finds Television and Climate Change on the Radar Business Wire
01:05AM  Pfizers 1Q16 Earnings: How Has Its Valuation Changed?
May-19-16 03:58PM  Why Spark Therapeutics Caught Fire and Rallied Higher Today at Motley Fool
03:36PM  Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
11:03AM  Pfizer's Hospira Unveils LifeCare PCA 7.0 Infusion System
08:30AM  Hospira Launches LifeCare PCA® 7.0 Infusion System, First PCA Pump That Integrates with the Electronic Medical Record Business Wire
06:30AM  Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression GlobeNewswire
05:33AM  Fed Should Not Raise Rates Now
04:55AM  U.N.'s rights chief urges firms to follow Pfizer's lead on death penalty Reuters
May-18-16 05:30PM  Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting Business Wire
05:30PM  Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting Business Wire
05:00PM  Pfizer's Ibrance delays breast cancer progression -study
05:00PM  Pfizer cancer drug shows promise in combo with Merck's Keytruda
05:00PM  Pfizer to Showcase Diverse and Growing Oncology Portfolio at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting Business Wire
03:44PM  Pfizer drug ban puts capital punishment in Tennessee further away at bizjournals.com
01:04PM  PFIZER INC Financials
09:09AM  IBB Mid-Cap News: Pfizer Acquired Anacor for $5.2 Billion
09:00AM  Gates Gets Surprise $87 Million From Neglected-Disease Stake
08:51AM  Pfizer Zeroes in on Anacor
08:51AM  Pfizer Zeroes in on Anacor Company Spotlight
06:06AM  Pfizer Purchases Anacor in a $5.2 Billion Cash Deal
02:41AM  Pascal Soriot's big experiment: reinventing AstraZeneca
May-17-16 05:26PM  Fitch Says Drug Approvals Are Driving Targeted Acquisitions In U.S. Pharma
04:13PM  Is Avoidance Of Morally Ambiguous Or Offensive Activities Justifiable In Corporate America?
03:20PM  Pfizer ban on lethal drug sales complicates executions in 20 U.S. states Reuters
02:44PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share -- ANAC PR Newswire
01:26PM  Block & Leviton LLP Investigates Anacor Pharmaceuticals Inc., Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Pfizer Inc. PR Newswire
11:40AM  Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead Zacks
11:22AM  A Look At All Of Pfizer's Acquisitions Over The Past 2 Years Benzinga
08:13AM  Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio Zacks
08:05AM  Pfizers Major Product Developments in 1Q16 Market Realist
08:05AM  Pfizers 1Q16 Earnings: What Contributed to Growth? Market Realist
08:00AM  Global Survey Finds Disconnects Between Physicians and People Living With Rheumatoid Arthritis (RA) Business Wire
07:08AM  Pfizer Buys Anacor Pharmaceuticals For $5.2B (PFE, ANAC) at Investopedia
12:11AM  [$$] Pfizer to Buy Anacor for $4.5 Billion at The Wall Street Journal
12:08AM  [$$] Biotech M&A: Pfizer Bets on Growth at The Wall Street Journal
May-16-16 07:13PM  Paulson & Co. sheds AbbVie, picks up more Pfizer at MarketWatch
06:00PM  Stocks End Higher on Back of Oil Rally Morningstar
05:53PM  Apple Inc. and Anacor Pharmaceuticals Inc. Soar As Stocks Jump at Motley Fool
05:47PM  US stocks climb in broad rally as crude oil rises AP
05:46PM  Business Highlights AP
05:33PM  Pfizer Acquiring Anacor For Potential Blockbuster Eczema Drug at Investor's Business Daily
05:23PM  Biz Break: Pfizer lays out $5.2 billion for Palo Altos Anacor Pharmaceuticals at San Jose Mercury News
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women's/men's health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has strategic collaboration with KineMed Inc.; collaborations with BIND Therapeutics, Inc., Merck KGaA, and Syndax Pharmaceuticals, Inc.; research collaboration with Schrdinger, Inc.; license and collaboration agreement with Servier; strategic drug discovery agreement with Heptares; and collaboration agreement with Portola Pharmaceuticals Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Option Exercise25.8726,000672,62096,113Jun 12 09:26 AM
OLSON LAURIE JExecutive Vice PresidentJun 11Sale34.3926,000894,15570,113Jun 12 09:26 AM